Diagnostic And Therapeutic Utility Of Gonadotrophin-Releasing Hormone Agonist In Postmenopausal Hyperandrogenism Of Ovarian Origin
July 2023
in “
Journal of the ASEAN Federation of Endocrine Societies
”
Studysummary In this study of a postmenopausal woman with hyperandrogenism, GnRH agonist treatment significantly reduced testosterone levels, suggesting the androgen excess was ovarian in origin and indicating the potential of using GnRH agonists as a conservative treatment option when surgery is not feasible.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study discusses the use of gonadotrophin-releasing hormone (GnRH) agonist as a diagnostic and therapeutic tool for postmenopausal hyperandrogenism of ovarian origin. A 71-year-old female with hirsutism and acne was treated with GnRH agonist, resulting in a significant reduction in testosterone levels (98.6% reduction) and clinical improvement, confirming the ovarian source of androgen excess. The study concludes that GnRH agonist can be a valuable tool for evaluating and conservatively treating postmenopausal hyperandrogenism, especially for patients who are not candidates for surgery.
